Maryam Ebrahimi Nik Selected Research

galbanic acid

7/2021	The effect of RGD-targeted and non-targeted liposomal Galbanic acid on the therapeutic efficacy of pegylated liposomal doxorubicin: From liposomal preparation to in-vivo studies.
2/2020	Author Correction: Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
1/2019	Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maryam Ebrahimi Nik Research Topics

Disease

6	Neoplasms (Cancer) 07/2021 - 01/2018
3	Carcinoma (Carcinomatosis) 02/2020 - 01/2019
2	Cardiovascular Diseases (Cardiovascular Disease) 05/2019 - 05/2019
1	Colonic Neoplasms (Colon Cancer) 07/2021
1	Melanoma (Melanoma, Malignant) 01/2020
1	Breast Neoplasms (Breast Cancer) 05/2019
1	Colorectal Neoplasms (Colorectal Cancer) 05/2019

Drug/Important Bio-Agent (IBA)

5	liposomal doxorubicin (Doxil)FDA Link 07/2021 - 01/2019
3	Liposomes (Liposome)IBA 07/2021 - 01/2019
3	galbanic acidIBA 07/2021 - 01/2019
3	VaccinesIBA 01/2020 - 05/2019
2	coumarinIBA 07/2021 - 01/2019
2	SesquiterpenesIBA 07/2021 - 01/2019
2	1-dodecylpyridoxal (PLD)IBA 05/2019 - 01/2019
2	PCSK9 InhibitorsIBA 05/2019 - 05/2019
1	cyclo(arginylglycyl)IBA 07/2021
1	arginyl-glycyl-aspartic acidIBA 07/2021
1	LigandsIBA 01/2019
1	fosbretabulin (combretastatin A4)IBA 01/2019
1	Peptides (Polypeptides)IBA 01/2018
1	AntigensIBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018

Therapy/Procedure

3	Therapeutics 07/2021 - 01/2019
1	Immunotherapy 01/2018